NextPlat Projects Profitability Ahead of Schedule, Fueled by 340B Growth and Pharmacy Acquisition
NXPL sits 72% above its 52-week low of $3.375 on light trading volume (0.2× avg).
Summary
NextPlat's mid-year update confirms a faster-than-expected path to profitability, driven by a surging healthcare segment. Q1 consolidated gross margins hit a record 35%, with the healthcare unit alone posting 39% margins—nearly double the prior year. Early Q2 data shows 340B prescriptions up over 70% year-over-year, and the company added six new 340B contracts, beating Q1's record of five. The recent $1.5M acquisition of Scott's Pharmacy adds roughly $5.6M in annual revenue and expands the Florida footprint. With over $11M in cash and no material long-term debt, the balance sheet supports further bolt-on deals. The AI-powered ClearMetrX 4.0 platform is now live with customers, automating prescription workflows.
At the time of this announcement, NXPL was trading at $5.81 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $15.7M. The 52-week trading range was $3.38 to $11.10. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.